Clever Culture Systems Limited · ASX:CC5
Clever Culture Systems — Investor Presentation (September 2018)
16 slides from Clever Culture Systems's investor presentation, Sep 17, 2018
Slide 1: Company Presentation – Australian Non Deal Roadshow
COMPANY PRESENTATION – AUSTRALIAN NON DEAL ROADSHOW Adelaide, Australia, 17 September 2018: LBT Innovations Limited (ASX: LBT) (LBT or the Company), a leader in medical technology automation using artificial intelligence is pleased to announce that Brent Barnes, CEO and Managing Director will be lea
Slide 2: LBT Innovations Limited (ASX:LBT) Company Presentation
ASX code: LBT lbtinnovations.com LBT Innovations Limited (ASX:LBT) Company Presentation Brent Barnes Chief Executive Officer & Managing Director September 2018
Slide 3: Disclaimer
Disclaimer This document contains certain forward-looking statements that involve risks and uncertainties. Although we believe that the expectations reflected in the forward-looking statements are reasonable at this time, we can give no assurance that these expectations will prove to be correct. Giv
Slide 4: Overview
Overview Artificial intelligence platform automating manual healthcare processes Commercial launch underway FDA cleared - 10,000 EU & AU - US late 2018 patient clinical study Cost and efficiency gains for Proprietary patented Pathology labs 3 times technology faster than manual reading Attractive re
Slide 5: Corporate Snapshot – ASX.LBT
Corporate Snapshot – ASX.LBT Key Statistics as at 14 Sep 2018 Financials Current Price $0.11 per share • $7.9m raised - fund LBT to cashflow positive in early 2020 • Cash as at 30 June ~$7.5m 12 month range $0.096 - $0.325 • Focus on early commercial launch & global footprint Shares Outstanding 200.
Slide 6: Problems facing our customers - Pathology laboratories
Problems facing our customers - Pathology laboratories Poor resource utilisation Recruiting Microbiologists • Up to 85% of plates can be negative • Average age of microbiologist is 51 years (AU)1, 42 (US)2 Ensuring consistent results • US vacancy rate at any one time is 9%3 • Known variability in mi
Slide 7: Launch Market - First Sale achieved August 18
Launch Market - First Sale achieved August 18 • Customer Evaluation – November 2017 • Confirmed utility and efficiencies in a “real life” clinical setting • > 3000 urine samples, automatically read and interpreted by APAS® Independence • Commercial sale – August 2018 • Terms undisclosed – pricing co
Slide 8: Multiple sales focus: Australian Launch Market
Multiple sales focus: Australian Launch Market • 1st sale achieved in August 2018 1. Raise 2. Verify 3. Budget, buying awareness clinical utility decision? • Positive market feedback • Pipeline sales targets identified, exact sales timing difficult to predict • Sales cycle 6 – 12+ months • Sales vis
Slide 9: 2018/19 Launch: Adoption & Footprint for scale
2018/19 Launch: Adoption & Footprint for scale Establishing early presence Germany: First placement at Labor Wisplinghoff (largest lab in DE). EU centre of excellence + on ground technical support. US: subject to pre launch (510(k) supplement) submission Launch Market Appointment of distributo
Slide 10: Attractive Revenue Model
Attractive Revenue Model End Customer Pricing 50:50 Joint Venture 5 year revenue Profits and costs shared opportunity Instrument Instrument once off ~USD$0.45m $$ development purchase price: per instrument ~USD$300,000 Annual Software License: ~USD$20K - $40K $$ *Distributor Margin $$ Legal manufact
Slide 11: Market Research: Sharpened focus on opportunity
Market Research: Sharpened focus on opportunity Macro Analysis Supporting Sales Validating the opportunity Ideal lab profile: 400+ plates per day which delivers ROI in 2.5 – 3.5yrs Over 100 labs, finalised Jul-18: Australia, UK, Germany, USA Feedback that influences customer interest and sales: Me
Slide 12: LBT advantage: AI in medical technology
LBT advantage: AI in medical technology Delivered capability – First Launch Ongoing Development + Strategy: Utilise platform technology Extend into new medical applications Leveraging developed core capability APAS® Independence Clinical Trials with Urine module Analysis Module for APAS®: More
Slide 13: Competitor Landscape – Culture plate workflow
Competitor Landscape – Culture plate workflow APAS® Independence Difference: • First & only FDA-Cleared: automated reading & interpretation • Modular in design • Affordable: USD$300K • Large market segment APAS® Independence Inoculation and Culture Automated Plate Identification & antibiotic Incubat
Slide 14: Similar product uptake in sector
Similar product uptake in sector MALDI-TOF: launched 2004 Previ Isola: launched 2009 Units placed Case Study APAS® globally MALDI-TOF: ~1500 units placed after 10 years Independence: ~12% global 1,500 penetration 1,500 units after 10 years 2 Manufacturers: 700 units placed in US Bruker & following F
Slide 15: APAS Development Evolution and Capital Management
APAS® Development Evolution and Capital Management • Invention to Launch - 8 years ~$24m • Commercialisation capital – recently secured > $10m to reach breakeven in 2 years • Current research validates the market need and that our technology remains unique $ cumulative spent $30m Capital Management
Slide 16: Brent Barnes Chief Executive Officer & Managing Director
Brent Barnes Chief Executive Officer & Managing Director Level 8, 44 Waymouth St, Adelaide SA 5000 P +61 (0)8 8227 1555 F +61 (0)8 8223 1775 info@lbtinnovations.com lbtinnovations.com © LBT Innovations 2018
Clever Culture Systems — Investor Presentation (September 2018) on 6ix